IMDX vs TPR · rev $271.0K vs P/E 46, rev $8.00B
Insight Molecular Diagnostics Inc. (IMDX) versus Tapestry Inc (TPR) — a side-by-side from cached financials, not a winner call.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Tapestry Inc (TPR) is a luxury goods company listed on NYSE.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
Latest reported TPR revenue for 2026-06-27 was $8.00B. Net income was $1.53B. Revenue was up 14.2% from 2025-06-28 to 2026-06-27. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
IMDX currently screens at market cap $0. TPR currently screens at market cap $30.81B and trailing P/E 46.3.
Not investment advice. Open the IMDX and TPR stock pages for the full models.
Not investment advice.